Alexion receives positive CHMP opinion for Soliris(R) (Eculizumab) in the EU
Alexion announced the CHMP of the EMA has adopted a positive opinion to extend the current therapeutic indication for Soliris® (eculizumab) to include treatment of refractory generalized myasthenia gravis in patients who are anti-acetylcholine receptor antibody-positive. June 23, 2017